Home Clinical Topics FDA approves drug for sexual desires disorders in women

FDA approves drug for sexual desires disorders in women

On Aug. 18, the U.S. Food and Drug Administration (FDA) approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here